GPs urged to be patient during initial stages of COVID vaccine rollout RACGP President Dr Karen Price says the patient-driven pivot to fewer doses across more practices represents a ‘slower, better, safer’ model for phase 1b.
Blocked vaccine shipment highlights importance of domestic production The stalled import could have affected the COVID vaccine rollout had Australia not secured local manufacturing capability.
COVID vaccine rollout: What GPs can learn from one doctor’s trial run As the nationwide rollout of AstraZeneca approaches, GP Dr Mukesh Haikerwal reveals the logistical realities exposed during a three-hour run through at his clinic.
Thousands of general practices to receive COVID vaccine doses within weeks A change in strategy will see all 4600 participating practices added to the rollout over four weeks, allowing more patients to be vaccinated by their own GP.
The moving parts of a nationwide vaccine rollout One of the largest logistical efforts in Australian general practice history will commence in less than a week.
Could a GP-led mass vaccination hub in Victoria set a national template? Grandstands around the country could be used to ramp up Australia’s COVID vaccine drive, following collaborative RACGP advocacy.
Three-hour mandatory vaccination training fails to consider GP expertise The RACGP is strongly advocating for any education and training to address GPs’ needs and avoid taking up critical time.
‘The beginning of the end of this pandemic’ The Oxford University/AstraZeneca coronavirus vaccine has been approved for use in Australia, while the first doses of Pfizer/BioNTech’s candidate will start being administered next week.
From the UK COVID frontline: what GPs can expect from the vaccine rollout GP Dr Colin Fitzpatrick talks to newsGP about coordinating the delivery of Pfizer/BioNTech vaccines across 110 Northern Ireland aged care facilities, and why they may not be suited to a nationwide rollout.
Efficacy rate alone not enough to determine overall value of a vaccine Many have highlighted AstraZeneca’s apparent 62% efficacy as a reason for Australia to seek out alternatives, but the candidate has a number of other significant advantages.